Attana now offers self sampling for expanded diagnostic testing capabilities with an updated CE IVD-marking
Attana now enables self sampling through an updated CE IVD-marking for capillary blood samples using Capitainer[®]qDBS cards (quantitative dried blood spot), enabling laboratories improved opportunities to perform immune profiling and monitoring of vaccine efficacy in broad patient populations.As presented together with Capitainer in February 2022, the goal of Attana Diagnostics is to offer broader and more patient-centric blood sampling solutions for the Attana AVA[TM] system. Since then, Attana has validated its AVA[TM] SARS-CoV-2 IgG Immunoassay kit for capillary blood samples, both qDBS